Antibody Fragments Market Report 2026

Antibody Fragments Market Overview

• Antibody Fragments market size has reached to $11.26 billion in 2025 • Expected to grow to $17.56 billion in 2030 at a compound annual growth rate (CAGR) of 9.3% • Growth Driver: Increasing Prevalence Of Target Diseases Fueling The Growth Of The Market Due To Rising Demand For Advanced Therapeutic Solutions • Market Trend: Focus On Human VH Antibody Fragments For Targeted Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Antibody Fragments Market?

Antibody fragments refer to smaller portions of antibodies that retain the ability to bind to specific antigens. They are derived from full-length antibodies and are designed to be more stable, penetrate tissues more effectively, and reduce immune system reactions, making them useful for therapeutic and diagnostic applications. The main types of antibody fragments include F(ab) fragments, F(ab’)₂ fragments, single-chain variable fragments (scFvs), single-domain antibody fragments (sdAbs), and other types. F(ab) fragments are antibody fragments with a single antigen-binding site, lacking the Fc region to reduce immune interactions, which enhances their diagnostic and therapeutic applications. Based on specificity, antibody fragments can be classified as monoclonal or polyclonal antibodies. They are delivered through intravenous (IV), subcutaneous (SC), oral, or transdermal methods and are used for various applications, including cancer treatment, immunodeficiencies, and other medical conditions. The key end users of antibody fragments include pharmaceutical companies, biotechnology companies, research institutions, diagnostic laboratories, and contract research organizations (CROs).

What Is The Antibody Fragments Market Growth Forecast?

The antibody fragments market size is expected to see strong growth in the next few years. It will grow to $17.56 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to growth in targeted cancer therapies, expansion of antibody fragment pipelines, increasing demand for precision biologics, rising use in companion diagnostics, innovation in recombinant antibody engineering. Major trends in the forecast period include rising adoption of fragment-based biologics, increasing use in oncology and targeted therapies, growing demand for high-penetration antibody formats, expansion of diagnostic applications, increased focus on reduced immunogenicity treatments.

Global Antibody Fragments Market Segmentation

1) By Type: F(ab) Fragments, F(ab’)2 Fragments, Single-Chain Variable Fragments (scFvs), Single Domain Antibody Fragments (sdAbs), Other Types 2) By Specificity: Monoclonal Antibody, Polyclonal Antibody 3) By Delivery Method: Intravenous (IV), Subcutaneous (SC) 4) By Application: Cancer, Immunodeficiencies, Other Applications 5) By End User: Pharmaceutical Companies, Biotechnology Companies, Research Institutions, Diagnostic Laboratories, Contract Research Organizations (CROs) Subsegments: 1) By F(ab) Fragments: Recombinant F(ab) Fragments, Enzymatically Derived F(ab) Fragments 2) By F(ab’)2 Fragments: Pepsin-Derived F(ab’)2 Fragments, Recombinant F(ab’)2 Fragments 3) By Single-Chain Variable Fragments (scFvs): Bacterial-Produced Single-Chain Variable Fragments (scFvs), Mammalian Cell-Produced Single-Chain Variable Fragments (scFvs), Yeast-Produced Single-Chain Variable Fragments (scFvs) 4) By Single Domain Antibody Fragments (sdAbs): Camelid-Derived Single Domain Antibody Fragments (sdAbs), Shark-Derived Single Domain Antibody Fragments (sdAbs), Synthetic Single Domain Antibody Fragments (sdAbs) 5) By Other Types: Bispecific Antibody Fragments, Multispecific Antibody Fragments, Fusion Protein Antibody Fragments

What Is The Driver Of The Antibody Fragments Market?

The increasing prevalence of target diseases is expected to propel the growth of the antibody fragments market going forward. Target diseases are specific illnesses or health conditions a medicine, treatment, or medical research aims to prevent, manage, or cure. The major target diseases include cancer, infectious diseases, and bacterial infections. The increasing prevalence of target diseases is mainly due to unhealthy lifestyles, and pollution weakens the body's defenses, which leads to chronic illnesses. Antibody fragments provide highly specific, targeted, and versatile options for treating various diseases, often with reduced side effects compared to traditional therapies. Their ability to be customized and engineered for specific targets makes them an increasingly valuable tool in modern medicine. For instance, in January 2025, according to a report published by the American Cancer Society, a US-based non-profit organization, in 2025, the United States is projected to report 2,041,910 new cancer cases and 618,120 cancer deaths, an increase from 2,001,140 new cases and 611,720 deaths in 2024. Therefore, the increasing prevalence of target diseases drives the growth of the antibody fragments industry.

Key Players In The Global Antibody Fragments Market

Major companies operating in the antibody fragments market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., UCB S.A., Bio-Rad Laboratories Inc., Genmab A/S, WuXi Biologics Co. Ltd., Abcam plc, MacroGenics Inc., Harbour BioMed, Creative Biolabs Inc.

Global Antibody Fragments Market Trends and Insights

Major companies operating in the antibody fragments market are focusing on conducting clinical trials to develop innovative products, such as human VH antibody fragments, to enhance targeted therapy effectiveness and reduce immunogenicity in treating cancers, autoimmune disorders, and infectious diseases. A human VH antibody fragment is the variable domain of the heavy chain of a human antibody, capable of binding to antigens independently. It helps form antibody fragments by serving as the essential antigen-binding region, often used alone or fused with other molecules to create small, stable, high-affinity therapeutic or diagnostic antibodies. For instance, in May 2024, Zai Lab Limited, a China-based pharmaceutical company, initiated a global Phase 2 clinical trial to evaluate the efficacy and safety of ZL-1102. ZL-1102 is a novel human VH antibody fragment (Humabody) that targets IL-17. It is being developed as a topical therapy for mild-to-moderate chronic plaque psoriasis to improve treatment precision while reducing systemic side effects and immunogenic responses.

What Are Latest Mergers And Acquisitions In The Antibody Fragments Market?

In September 2024, Valerio Therapeutics S.A., a France-based clinical-stage biotechnology company, acquired Emglev Therapeutics for an undisclosed amount. With this acquisition, Valerio Therapeutics strengthens its antibody discovery capabilities by integrating Emglev Therapeutics’ synthetic single-domain antibody (sdAb) technology to expand therapeutic applications. Emglev Therapeutics is a France-based biotechnology company specializing in developing synthetic single-domain antibody (sdAb).

Regional Insights

North America was the largest region in the antibody fragments market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Antibody Fragments Market?

The antibody fragments market consists of revenues earned by entities by providing services such as pharmacokinetics and toxicology testing, clinical and regulatory support services, custom conjugation services, and antibody fragment production and expression services. The market value includes the value of related goods sold by the service provider or included within the service offering. The antibody fragments market also includes sales of diabodies and tribodies, nanobodies, antibody-based therapeutics, and diagnostic agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Antibody Fragments Market Report 2026?

The antibody fragments market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the antibody fragments industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.